Related Experiment Video
Updated: Dec 27, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
L-arginase induces vascular dysfunction in old spontaneously hypertensive rats
O Arishe1,2, J McKenzie1, F Priviero1
1Department of Physiology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Arginase impairs vascular function in aging rats by reducing nitric oxide (NO) availability, contributing to hypertension. This study highlights arginase as a key factor in age-related vascular dysfunction.
Area of Science:
- Vascular Biology
- Aging Research
- Hypertension
Background:
- Aging is a significant risk factor for hypertension, sharing similarities with vascular changes seen in hypertensive conditions.
- Arginase activity reduces L-arginine availability, decreasing nitric oxide (NO) production, leading to impaired vasodilation and vascular dysfunction.
Purpose of the Study:
- To investigate the hypothesis that arginase mediates age-dependent vascular dysfunction in spontaneously hypertensive rats (SHRs).
Main Methods:
- Compared young and old Wistar and SHR rats, measuring mean arterial pressure (MAP).
- Assessed vascular reactivity in mesenteric resistance arteries (MRAs) and thoracic aortae using acetylcholine (Ach) and sodium nitroprusside (SNP) in the presence or absence of L-arginase.
Main Results:
- MAP increased with age in SHRs but not Wistar rats.
- Arginase significantly impaired endothelium-dependent relaxation to Ach in old Wistar and SHR vessels.
- Arginase also impaired endothelium-independent relaxation to SNP in old SHRs.
Conclusions:
- Arginase negatively impacts both endothelium-dependent and -independent vasorelaxation.
- These effects are mediated through the nitric oxide (NO) signaling pathway, implicating arginase in age-related vascular dysfunction.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Vasodilators
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

